Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 17/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1232744 | 0.94 | LIPG (0.39) | TLR7TLR8LIPGKDM4EUSP2 | |
| SCHEMBL1231786 | 0.92 | TLR7 (0.40) | TLR7TLR8KDM4EUSP2ALDH1A1 | |
| SCHEMBL12888471 | 0.86 | TLR7 (0.41) | TLR7TLR8LIPGKDM4EUSP2 | |
| SCHEMBL1233130 | 0.85 | GBA1 (0.40) | TLR7TLR8KDM4EUSP2ALDH1A1 | |
| SCHEMBL1232440 | 0.81 | TLR7 (0.39) | TLR7TLR8KDM4EALDH1A1GLA | |
| SCHEMBL1232937 | 0.81 | PKM (0.33) | TLR7ALDH1A1TSHR | |
| SCHEMBL1232864 | 0.79 | HRH4 (0.38) | TLR7TLR8KDM4EALDH1A1GAA | |
| SCHEMBL1233129 | 0.79 | GBA1 (0.43) | TLR7TLR8LIPGKDM4EALDH1A1 | |
| SCHEMBL1232669 | 0.78 | HRH4 (0.37) | TLR7KDM4EUSP2ALDH1A1HPGD | |
| SCHEMBL1233314 | 0.78 | TLR7 (0.39) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888349-B2 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | IL4, IL2, IL5 | TLR7 821/4885TLR8 958/4885LIPG 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.